Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Expected to Post Earnings of -$0.76 Per Share

Posted by Chris Copeland on Dec 2nd, 2019

Brokerages predict that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will report earnings per share (EPS) of ($0.76) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Lexicon Pharmaceuticals’ earnings, with estimates ranging from ($0.80) to ($0.71). Lexicon Pharmaceuticals reported earnings of ($0.16) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 375%. The business is scheduled to issue its next quarterly earnings report on Wednesday, March 11th.

On average, analysts expect that Lexicon Pharmaceuticals will report full year earnings of $0.83 per share for the current year, with EPS estimates ranging from $0.78 to $0.87. For the next year, analysts forecast that the firm will report earnings of ($1.96) per share, with EPS estimates ranging from ($2.40) to ($1.55). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that that provide coverage for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $2.11 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.80. The business had revenue of $294.45 million for the quarter, compared to analysts’ expectations of $12.00 million. Lexicon Pharmaceuticals had a return on equity of 2,372.40% and a net margin of 49.78%. The business’s revenue was up 4124.5% on a year-over-year basis. During the same period last year, the business earned ($0.26) EPS.

A number of research analysts recently weighed in on LXRX shares. Wedbush reissued a “buy” rating and set a $17.00 price target on shares of Lexicon Pharmaceuticals in a research report on Wednesday, November 13th. Citigroup cut Lexicon Pharmaceuticals from a “buy” rating to a “neutral” rating and increased their price objective for the stock from $3.00 to $4.00 in a report on Friday, November 8th. ValuEngine upgraded shares of Lexicon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 2nd. BidaskClub downgraded shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, November 27th. Finally, Zacks Investment Research cut shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 16th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company’s stock. Lexicon Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $6.45.

Shares of NASDAQ LXRX traded down $0.52 during trading on Wednesday, hitting $3.01. The stock had a trading volume of 83,326 shares, compared to its average volume of 1,170,697. The firm has a fifty day moving average of $3.62 and a two-hundred day moving average of $3.95. The company has a market capitalization of $375.14 million, a PE ratio of -2.64 and a beta of 1.00. The company has a debt-to-equity ratio of 1.42, a current ratio of 8.11 and a quick ratio of 8.01. Lexicon Pharmaceuticals has a 12 month low of $1.13 and a 12 month high of $8.40.

In related news, Director Christopher J. Sobecki purchased 99,249 shares of the firm’s stock in a transaction on Friday, September 13th. The shares were acquired at an average cost of $2.41 per share, with a total value of $239,190.09. Following the purchase, the director now directly owns 13,645 shares of the company’s stock, valued at $32,884.45. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Christopher J. Sobecki acquired 25,000 shares of the business’s stock in a transaction dated Monday, September 16th. The stock was acquired at an average price of $2.55 per share, for a total transaction of $63,750.00. Following the completion of the transaction, the director now owns 112,493 shares in the company, valued at approximately $286,857.15. The disclosure for this purchase can be found here. Insiders purchased 178,749 shares of company stock worth $474,560 over the last ninety days. 6.40% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in LXRX. Commonwealth Equity Services LLC grew its stake in shares of Lexicon Pharmaceuticals by 40.5% in the 3rd quarter. Commonwealth Equity Services LLC now owns 16,461 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 4,746 shares during the last quarter. Quantitative Systematic Strategies LLC raised its position in shares of Lexicon Pharmaceuticals by 67.2% in the 2nd quarter. Quantitative Systematic Strategies LLC now owns 20,648 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 8,302 shares during the last quarter. State Street Corp boosted its stake in Lexicon Pharmaceuticals by 1.5% in the 3rd quarter. State Street Corp now owns 952,606 shares of the biopharmaceutical company’s stock worth $2,867,000 after purchasing an additional 13,654 shares in the last quarter. Swiss National Bank increased its stake in Lexicon Pharmaceuticals by 18.3% during the 2nd quarter. Swiss National Bank now owns 88,614 shares of the biopharmaceutical company’s stock valued at $557,000 after purchasing an additional 13,700 shares in the last quarter. Finally, Trexquant Investment LP bought a new stake in Lexicon Pharmaceuticals during the 2nd quarter valued at about $92,000. 96.27% of the stock is owned by institutional investors.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.